SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software

Posted on by Tina Guvench

FOR IMMEDIATE RELEASE: July 12, 2018 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software July 12, 2018 Baltimore, Maryland: SilcsBio, LLC (SilcsBio) announced today the issuance of a US patent covering key elements of SilcsBio’s drug design software. The SilcsBio software is broadly used[…]

SILCS-MC ranks top 10 on Free Energy Set 1 in the D3R Grand Challenge 2 on FXR

Posted on by Tina Guvench

Grand Challenge 2 from D3R provided a farnesoid X receptor (FXR) target dataset to participants, which was used to test the performance of various computational approaches. SilcsBio’s SILCS-MC approach ranked 4th in Stage 1 and 6th in Stage 2 on the Free Energy Set 1 of this challenge. We used our unique SILCS approach to[…]